tralokinumab

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-S

Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients1 Patients enrolled in ECZTRA 1 and 2 parent tr…
财经要闻
- 35
- 0
秋风4 年前